| Prev Close | 4.13 |
| Open | 4.13 |
| Day Low/High | 4.00 / 4.38 |
| 52 Wk Low/High | 1.53 / 2.72 |
| Volume | 20.88K |
| Avg Volume | 85.70K |
| Exchange | NASDAQ |
| Shares Outstanding | 6.59M |
| Market Cap | 27.22M |
| EPS | -2.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Pain Therapeutics Announces Reverse Stock Split
Stock to Trade on a Split-adjusted Basis Beginning May 10, 2017
Pain Therapeutics Announces Positive Regulatory Guidance For REMOXY™ ER
- Company Will Host Conference Call on Tuesday, March 21st, at 8am Eastern Time -
5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy
Here's a technical look at how to trade some of the most active stocks on the market right now.
For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million
Failure is very profitable for Pain Therapeutics CEO Remi Barbier.
Putting 2 Biotechs Under the Microscope
These low-dollar biotech stocks are making big moves Monday -- in opposite directions.
Complete Response Letter For REMOXY®
Company Will Host Conference Call Monday, September 26th at 9:00am EDT
DURECT Provides REMOXY® Update
Pain Therapeutics Announced today that an FDA Advisory Committee Meeting for REMOXY® is Not Needed and No Change to September 25, 2016 PDUFA Date
Pain Therapeutics Announces Advisory Committee Meeting For REMOXY® Is Not Needed
No Change to September 25th PDUFA Date
DURECT Announces FDA Advisory Committee Meeting For REMOXY®
FDA's Tentative Date for Advisory Committee Meeting is August 5, 2016 and No Change to PDUFA Date of September 25, 2016
Pain Therapeutics Resubmits REMOXY New Drug Application To The U.S. Food And Drug Administration
REMOXY NDA Has Priority Review
Pain Therapeutics Reports 2015 Financial Results And Corporate Update
Focus in 2016 Will be on REMOXY, Fiscal Discipline and Advancing Pipeline
Pain Therapeutics Reports Q3 2015 Financial Results And Update On REMOXY
Focus Remains on NDA Resubmission to FDA, Targeted for Q1 2016
Short Interest In Pain Therapeutics Makes 27.2% Move
The most recent short interest data has been released by the NASDAQ for the 05/29/2015 settlement date, which shows a 650,044 share increase in total short interest for Pain Therapeutics Inc , to 3,037,711, an increase of 27.23% since 05/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.